Is Ditto Biosciences profitable?

No. As of July 2026, Ditto Biosciences is a 3-person, pre-clinical, platform-stage biotech with no reported product revenue. Its business is scanning parasite, virus, and tick genomes for autoimmune drug candidates, not yet a marketed therapy or licensing deal.

Could AI replace Ditto Biosciences?

Ditto's own discovery method, protein-language and structure-prediction models scanning pathogen genomes, is itself AI-native and could be replicated by better-funded rivals like Xaira Therapeutics, which raised a $1B seed in 2024 with an explicit inflammation/immunology focus, as of March 2026.

Who are Ditto Biosciences' biggest competitors?

Xaira Therapeutics ($1B seed, 2024, David Baker, explicit I&I focus), Nabla Bio (Takeda collaboration worth over $1B in milestones, per July 2026 reporting), Generate:Biomedicines (publicly traded, Phase I pipeline), and Chai Discovery ($130M Series B, per March 2026 Fierce Biotech).

Is it risky to join Ditto Biosciences?

Yes, structurally. As of July 2026, it is a 3-employee seed-stage startup with no peer-reviewed validation of its own discovery platform yet, competing against $1B-plus funded or publicly traded rivals in the same autoimmune AI-discovery niche.

What is Ditto Biosciences' actual moat?

A proprietary tissue biobank mapping human immune-memory samples to parasite proteins, intended to improve immunogenicity prediction, per its February 2026 YC launch. As of mid 2026 this biobank is a stated roadmap asset, not yet built at defensible scale.

Who owns Ditto Biosciences?

Ditto Biosciences is privately held, founded in 2025 by three PhD scientists, Dennis Sun (CEO), Adair Borges (CSO), and Emily Weiss (CTO), and went through Y Combinator's Winter 2026 batch. No parent company or acquisition has been reported.

YC Winter 2026 · United States

Ditto Biosciences

dittobio.com ↗

Early biotech using AI to mine parasite and virus proteins for autoimmune drug candidates.

Losing its protection

Assessed 27 July 2026 · Evidence as of 27 July 2026

The structural protection is eroding.

On the recordSince 27 July 2026 · Checkable from unspecified, watch next 12 months · Every call on the record Checkpoint: First peer-reviewed or preprint validation of a Ditto-discovered candidate showing in vivo efficacy

The call

Ditto has a real, unclaimed niche in parasite biology, but nothing yet stops Xaira or Nabla from entering it once they decide it's worth the detour.

Ditto Biosciences uses artificial intelligence to find new drug ideas from parasites that might help treat autoimmune diseases like lupus or rheumatoid arthritis. Right now, the company has picked an area that larger competitors like Xaira Therapeutics and Nabla Bio have not yet focused on, but those rivals have more money, better-known scientists, and the same AI tools that Ditto uses; there is nothing stopping them from copying Ditto's approach and moving into the same space. The one thing that could shift this situation is if Ditto builds a large collection of human tissue samples from sick patients that competitors cannot easily replace, or if Ditto gets a drug candidate into human testing and shows it actually works before the bigger companies make their move.

Why

AI pressure: Protein-language/structure models (AlphaFold-descendant tools) used by any funded team. AI models make the front-end discovery step easy to copy, so scanning parasite proteomes is no longer Ditto's alone to do. Could AI do the core job? Yes, likely.

Bigger players: Xaira Therapeutics, Nabla Bio, Generate:Biomedicines. Xaira has $1B and an explicit inflammation/immunology focus; Nabla has a $1B+ Takeda deal; neither has published on parasite-derived candidates yet, but both could pivot fast. Could a giant copy it? Yes, easily.

What protects it. A proprietary tissue biobank linking human immune memory to parasite proteins, if it gets built at real scale before rivals notice the niche.

What would change this call

Xaira Therapeutics or Nabla Bio publish work on pathogen-derived immunomodulator discovery. Would show larger, better-funded rivals closing Ditto's niche window.
Ditto announces a Series A round with named lead investor. Would show capital and validation needed to compete on speed with rivals.
Ditto or independent researchers publish in vivo efficacy data for a parasite-derived candidate. Would show the core scientific thesis is validated rather than speculative.

Key numbers

3 employees as of mid-2026 (2026-07-25)
Xaira raised $1B seed round (2026-03-17)
Nabla Bio Takeda deal worth $1B+ in milestones (2026-07-16)

Named risks

Core discovery methodology is AI-native and replicable by far better-funded rivals. Severity: high
No independent or peer-reviewed validation of any Ditto-discovered candidate as of July 2026. Severity: high
Stated moat, the tissue biobank, is roadmap-stage and not yet built at scale. Severity: medium
Only 3 employees and unconfirmed funding details heighten execution risk. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Xaira Therapeutics	losing to	$1B seed 2024, explicit I&I focus, unveiled AI cell model March 2026
Nabla Bio	losing to	Takeda deal >$1B milestones, published de novo antibody results Nov 2024
Generate:Biomedicines	losing to	Publicly traded with multiple Phase I trials as of Aug 2025
Chai Discovery	contesting	$130M Series B closed, similar early-stage AI antibody design, March 2026

Questions people ask

Is Ditto Biosciences profitable?: No. As of July 2026, Ditto Biosciences is a 3-person, pre-clinical, platform-stage biotech with no reported product revenue. Its business is scanning parasite, virus, and tick genomes for autoimmune drug candidates, not yet a marketed therapy or licensing deal.
Could AI replace Ditto Biosciences?: Ditto's own discovery method, protein-language and structure-prediction models scanning pathogen genomes, is itself AI-native and could be replicated by better-funded rivals like Xaira Therapeutics, which raised a $1B seed in 2024 with an explicit inflammation/immunology focus, as of March 2026.
Who are Ditto Biosciences' biggest competitors?: Xaira Therapeutics ($1B seed, 2024, David Baker, explicit I&I focus), Nabla Bio (Takeda collaboration worth over $1B in milestones, per July 2026 reporting), Generate:Biomedicines (publicly traded, Phase I pipeline), and Chai Discovery ($130M Series B, per March 2026 Fierce Biotech).
Is it risky to join Ditto Biosciences?: Yes, structurally. As of July 2026, it is a 3-employee seed-stage startup with no peer-reviewed validation of its own discovery platform yet, competing against $1B-plus funded or publicly traded rivals in the same autoimmune AI-discovery niche.
What is Ditto Biosciences' actual moat?: A proprietary tissue biobank mapping human immune-memory samples to parasite proteins, intended to improve immunogenicity prediction, per its February 2026 YC launch. As of mid 2026 this biobank is a stated roadmap asset, not yet built at defensible scale.
Who owns Ditto Biosciences?: Ditto Biosciences is privately held, founded in 2025 by three PhD scientists, Dennis Sun (CEO), Adair Borges (CSO), and Emily Weiss (CTO), and went through Y Combinator's Winter 2026 batch. No parent company or acquisition has been reported.

Timeline

2026-07-25YC directory lists Ditto Biosciences headcount at 3 employees
2026-07-17AI-news blog profiles Ditto Bio's parasite-mining approach
2026-03-17Rival Xaira Therapeutics unveils AI cell model, details I&I R&D focus
2026-03-05Ditto Bio covered in BioByte 150 biotech newsletter roundup
2026-02-05Ditto Bio publicly launches via Y Combinator W26 batch
2025-01-20Rival Nabla Bio posts bioRxiv preprint on epitope-specific antibody design
2024-11-21Rival Nabla Bio publishes de novo antibody design results (JAM system)
2024Rival Xaira Therapeutics raises headline $1B seed round

Revision history

27 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

CellType OctaPulse The Token Company